An Emerging Class of Long Non-coding RNA With Oncogenic Role Arises From the snoRNA Host Genes

Zimța, Alina-Andreea; Țigu, Adrian Bogdan; Braicu, Cornelia; Stefan, Cristina; Ionescu, Călin

doi:10.3389/fonc.2020.00389

Cited by 112 publications

(119 citation statements)

References 207 publications

Supporting

Mentioning

105

Contrasting

Order By: Relevance

“…Nanoparticle-based small ncRNA vectors are the most common strategy [ 89 ]. SNHG3 is located in the nucleus and cytoplasm and requires a carrier to transport antisense RNAs or siRNAs into the cell to function [ 90 ]. Therefore, through continuous progress of antisense RNA or siRNA and ncRNA vectors, direct silencing of SNHG3 has become an important and powerful new target for tumor treatment.…”

Section: Perspectives In Clinical Practicementioning

confidence: 99%

LncRNA SNHG3, a potential oncogene in human cancers

Mei

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are composed of > 200 nucleotides; they lack the ability to encode proteins but play important roles in a variety of human tumors. A large number of studies have shown that dysregulated expression of lncRNAs is related to tumor oncogenesis and progression. Emerging evidence shows that SNHG3 is a novel oncogenic lncRNA that is abnormally expressed in various tumors, including osteosarcoma, liver cancer, lung cancer, etc. SNHG3 primarily competes as a competitive endogenous RNA (ceRNA) that targets tumor suppressor microRNAs (miRNAs) and ceRNA mechanisms that regulate biological processes of tumors. In addition, abnormal expression of SNHG3 is significantly correlated with patient clinical features. Upregulation of SNHG3 contributes to biological functions, including tumor cell proliferation, migration, invasion and EMT. Therefore, SNHG3 may represent a potential diagnostic and prognostic biomarker, as well as a novel therapeutic target.

show abstract

Section: Perspectives In Clinical Practicementioning

confidence: 99%

LncRNA SNHG3, a potential oncogene in human cancers

Mei

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

show abstract

“…The oncogenic role of SNHGs in diverse human cancers is supported by solid scientific data, which show that they are related to stimulation of the following malignant processes: epithelial to mesenchymal transition, invasion, proliferation, cell cycle, and apoptosis evasion. 9 We intended to test the SNHGs expression and determined their clinical implication in AML. In this study, we for the first time revealed clinical implications of SNHGs expression in AML.…”

Section: Discussionmentioning

confidence: 99%

“…7,8 Small nucleolar RNA host gene (SNHG) family members (SNHGs) including SNHG1, SNHG2/GAS5, SNHG3, SNHG4, SNHG5, SNHG6, SNHG7, SNHG8, SNHG9, SNHG10, SNHG11, SNHG12, SNHG13/DANCR, SNHG15, SNHG17, SNHG20 and SNHG28, are newly recognized lncRNAs, which have been revealed to be oncogenes in several cancers. 9 Also, several members of SNHG family including SNHG1, SNHG3, and SNHG5 have been found to be dysregulated and play a crucial role in leukemogenesis, and also have prognostic value in AML. [10][11][12][13][14] Since little studies investigated the expression and clinical implications of SNHGs in AML, we systemically determined the prognostic role of SNHGs expression in patients with AML.…”

Section: Introductionmentioning

confidence: 99%

<p>Identification of Long Non-Coding RNA <em>SNHG</em> Family as Promising Prognostic Biomarkers in Acute Myeloid Leukemia</p>

Shi¹,

Ding²,

Lü³

2020

OTT

View full text Add to dashboard Cite

Background: Small nucleolar RNA host gene (SNHG) family members are newly recognized lncRNAs, which have been revealed to be oncogenes in several cancers. However, little studies investigated the expression and clinical implications of SNHGs in AML. Methods: Herein, we systemically determined the prognostic role of the expression of SNHG family members in acute myeloid leukemia (AML). Results: Among the expression of all SNHG family members, we identified that only SNHG7 and SNHG12 expression were found to have prognostic effects on overall survival (OS) and leukemia-free survival (LFS) in AML by Cox regression univariate analysis. Furthermore, Kaplan-Meier analysis showed that SNHG7 higher-expressed cases had markedly longer OS and LFS time than SNHG7 lower-expressed cases, whereas SNHG12 higher-expressed cases had markedly shorter OS and LFS time than SNHG12 lower-expressed cases. Interestingly, SNHG7 and SNHG12 expression were also associated with several prognosis-related clinical/molecular features such as white blood cell counts, FAB/cytogenetic classifications, IDH1 mutation, RUNX1 mutation, and NPM1 mutation. Despite the associations, Cox regression multivariate analysis confirmed the independent prognostic impact of SNHG7 and SNHG12 expression in AML. Notably, we further validated that both SNHG7 and SNHG12 expression was significantly increased in newly diagnosed AML patients. Conclusion: Our findings demonstrated that SNHG7 and SNHG12 expression act as independent prognostic indicators in AML.

show abstract

“…Therefore, patient care management remains an important clinical challenge due to the lack of availability of prognostic markers that could stratify a patient’s risk. In the past few years, there has been an increased interest in verifying the clinical utility of coding and noncoding genes as important biomarkers for prognostic, diagnostic, and therapeutic targets [ 2 , 4 , 5 , 6 , 7 , 8 ].…”

Section: Introductionmentioning

confidence: 99%

Cancer-Associated Stemness and Epithelial-to-Mesenchymal Transition Signatures Related to Breast Invasive Carcinoma Prognostic

Groza

Braicu

Jurj

et al. 2020

Cancers

Self Cite

View full text Add to dashboard Cite

Breast cancer is one of the most common oncological diseases in women, as its incidence is rapidly growing, rendering it unpredictable and causing more harm than ever before on an annual basis. Alterations of coding and noncoding genes are related to tumorigenesis and breast cancer progression. In this study, several key genes associated with epithelial-to-mesenchymal transition (EMT) and cancer stem cell (CSC) features were identified. EMT and CSCs are two key mechanisms responsible for self-renewal, differentiation, and self-protection, thus contributing to drug resistance. Therefore, understanding of the relationship between these processes may identify a therapeutic vulnerability that can be further exploited in clinical practice, and evaluate its correlation with overall survival rate. To determine expression levels of altered coding and noncoding genes, The Cancer Omics Atlas (TCOA) are used, and these data are overlapped with a list of CSCs and EMT-specific genes downloaded from NCBI. As a result, it is observed that CSCs are reciprocally related to EMT, thus identifying common signatures that allow for predicting the overall survival for breast cancer genes (BRCA). In fact, common CSCs and EMT signatures, represented by ALDH1A1, SFRP1, miR-139, miR-21, and miR-200c, are deemed useful as prognostic biomarkers for BRCA. Therefore, by mapping changes in gene expression across CSCs and EMT, suggesting a cross-talk between these two processes, we have been able to identify either the most common or specific genes or miRNA markers associated with overall survival rate. Thus, a better understanding of these mechanisms will lead to more effective treatment options.

show abstract

An Emerging Class of Long Non-coding RNA With Oncogenic Role Arises From the snoRNA Host Genes

Cited by 112 publications

References 207 publications

LncRNA SNHG3, a potential oncogene in human cancers

LncRNA SNHG3, a potential oncogene in human cancers

<p>Identification of Long Non-Coding RNA <em>SNHG</em> Family as Promising Prognostic Biomarkers in Acute Myeloid Leukemia</p>

Cancer-Associated Stemness and Epithelial-to-Mesenchymal Transition Signatures Related to Breast Invasive Carcinoma Prognostic

Contact Info

Product

Resources

About